Guardant Health, Inc. (NASDAQ:GH) Stake Lifted by Blue Water Life Science Advisors LP

Blue Water Life Science Advisors LP raised its stake in Guardant Health, Inc. (NASDAQ:GHGet Rating) by 69.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 661,445 shares of the company’s stock after purchasing an additional 270,500 shares during the quarter. Guardant Health comprises about 20.8% of Blue Water Life Science Advisors LP’s investment portfolio, making the stock its 2nd biggest position. Blue Water Life Science Advisors LP owned 0.65% of Guardant Health worth $43,814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Capital Research Global Investors lifted its stake in shares of Guardant Health by 50.0% in the fourth quarter. Capital Research Global Investors now owns 7,927,702 shares of the company’s stock worth $792,929,000 after acquiring an additional 2,640,910 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Guardant Health by 8.0% during the 1st quarter. Clearbridge Investments LLC now owns 3,354,024 shares of the company’s stock worth $222,171,000 after purchasing an additional 247,486 shares during the last quarter. Capital International Investors increased its holdings in Guardant Health by 38.0% during the 4th quarter. Capital International Investors now owns 2,971,384 shares of the company’s stock worth $297,198,000 after purchasing an additional 818,309 shares during the last quarter. Geode Capital Management LLC increased its holdings in Guardant Health by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 1,251,161 shares of the company’s stock worth $125,141,000 after purchasing an additional 28,988 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Guardant Health by 5.3% during the 1st quarter. American Century Companies Inc. now owns 1,057,870 shares of the company’s stock worth $70,074,000 after purchasing an additional 52,772 shares during the last quarter. 89.36% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Guardant Health news, SVP Amelia Merrill sold 4,500 shares of the business’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $53.38, for a total transaction of $240,210.00. Following the completion of the transaction, the senior vice president now owns 24,708 shares in the company, valued at approximately $1,318,913.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Guardant Health news, insider Kumud Kalia sold 2,000 shares of the business’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $51.39, for a total transaction of $102,780.00. Following the completion of the transaction, the insider now owns 18,530 shares in the company, valued at approximately $952,256.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Amelia Merrill sold 4,500 shares of the business’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $53.38, for a total value of $240,210.00. Following the completion of the sale, the senior vice president now directly owns 24,708 shares in the company, valued at approximately $1,318,913.04. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Guardant Health Trading Down 3.0 %

NASDAQ:GH opened at $59.18 on Wednesday. Guardant Health, Inc. has a 12-month low of $27.65 and a 12-month high of $132.87. The firm has a market capitalization of $6.05 billion, a P/E ratio of -10.94 and a beta of 0.80. The company has a debt-to-equity ratio of 3.56, a current ratio of 6.18 and a quick ratio of 5.83. The business has a 50 day simple moving average of $51.01 and a 200 day simple moving average of $51.69.

Guardant Health (NASDAQ:GHGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.00). Guardant Health had a negative net margin of 135.03% and a negative return on equity of 99.90%. The company had revenue of $109.14 million for the quarter, compared to analyst estimates of $105.14 million. During the same quarter in the prior year, the firm earned ($0.96) EPS. The company’s revenue for the quarter was up 18.5% compared to the same quarter last year. Equities research analysts predict that Guardant Health, Inc. will post -6.12 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. The Goldman Sachs Group dropped their price objective on Guardant Health from $90.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, August 8th. OTR Global downgraded Guardant Health to a “positive” rating in a report on Monday, August 1st. Credit Suisse Group initiated coverage on Guardant Health in a report on Wednesday, August 24th. They issued an “outperform” rating and a $80.00 price target for the company. Morgan Stanley lowered their price target on Guardant Health from $85.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, August 8th. Finally, Piper Sandler initiated coverage on Guardant Health in a report on Thursday, June 2nd. They issued an “overweight” rating and a $65.00 price target for the company. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health currently has an average rating of “Buy” and a consensus price target of $115.75.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.